Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7025069rdf:typepubmed:Citationlld:pubmed
pubmed-article:7025069lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0033567lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0238217lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0205178lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0205217lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0870883lld:lifeskim
pubmed-article:7025069lifeskim:mentionsumls-concept:C0205360lld:lifeskim
pubmed-article:7025069pubmed:issue1lld:pubmed
pubmed-article:7025069pubmed:dateCreated1981-11-18lld:pubmed
pubmed-article:7025069pubmed:abstractTextIn 30 patients after kidney transplantation, 6-oxo-PGF1 alpha was examined in unextracted plasma by a specific radioimmunoassay. The material was divided into three groups. Patients with acute transplant rejection showing the highest 6-oxo-PGF1 alpha levels, patients with delayed transplant rejection having significantly lower plasma values and a third group of patients with stable transplant function. In these patients the plasma 6-oxo-PGF1 alpha-values were below the lower limit of detection (70 pg/ml). The enhanced 6-oxo-PGF1 alpha during rejection crisis could be interpreted as a self protection mechanism of vascular tissue which is, however, not sufficient in many cases, to prevent the irreversible rejection of the transplant.lld:pubmed
pubmed-article:7025069pubmed:languageenglld:pubmed
pubmed-article:7025069pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025069pubmed:citationSubsetIMlld:pubmed
pubmed-article:7025069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025069pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7025069pubmed:statusMEDLINElld:pubmed
pubmed-article:7025069pubmed:monthJullld:pubmed
pubmed-article:7025069pubmed:issn0161-4630lld:pubmed
pubmed-article:7025069pubmed:authorpubmed-author:LeithnerCClld:pubmed
pubmed-article:7025069pubmed:authorpubmed-author:SinzingerHHlld:pubmed
pubmed-article:7025069pubmed:authorpubmed-author:PeskarB ABAlld:pubmed
pubmed-article:7025069pubmed:issnTypePrintlld:pubmed
pubmed-article:7025069pubmed:volume7lld:pubmed
pubmed-article:7025069pubmed:ownerNLMlld:pubmed
pubmed-article:7025069pubmed:authorsCompleteYlld:pubmed
pubmed-article:7025069pubmed:pagination15-8lld:pubmed
pubmed-article:7025069pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:meshHeadingpubmed-meshheading:7025069-...lld:pubmed
pubmed-article:7025069pubmed:year1981lld:pubmed
pubmed-article:7025069pubmed:articleTitleIncreased plasma levels of 6-oxo-prostaglandin F1 alpha, a stable metabolite of prostacyclin, in acute kidney transplant rejection.lld:pubmed
pubmed-article:7025069pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7025069pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7025069lld:pubmed